Patients had failed therapy with phenobarbital, primidone, phenytoin, carbamazepine and valproic acid alone or in various combinations.
Decreases in carbamazepine serun concentrations occurred after starting methsuximide as an adjunctive anti-epileptic. OCIVMENr.
Methsuximide has been reported of benefit in the treatment of petit mal, partial myoclonic, atonic and tonic seizures.
As monotherapy methsuximide is not well established, but as an adjunct therapy further trials should be considered. Skin rash is not unccnmon and methsuximide may be contraindicated in patients with a history of hypersensitivity reactions to other anticonvulsants.
VAGUS NERVE STIMULATION FOR OCKIRPL OF EPILEPSY
Results of intermittent stimulation of the vagus nerve in four patients with intractable partial seizures are reported from the Department of Neurology, Bowman Gray School of Medicine, Wake Forest University, Wins ton-Sal an, NC.
The criteria for implantation of the device were 1) refractory partial seizures, 2) adequate trials of anti-epileptic drugs, 3) adequate trials of investigational drugs, 4) age 18 to 55 and 5) not a candidate for epilepsy brain surgery.
The stimulation electrodes are placed around the vagus nerve at or above the omohyoid muscle. The leads are tunneled through to a subcutaneous pocket in the subclavicular region and connected to the pulse genera¬ tor.
Complex and simple partial seizures as well as secondarily generalized seizures were reduced by 100% in patients 1 and 2 and by 40% in patient 4.
Side effects were transient and occurred concomi¬ tantly with stimulation and included hoarseness and a stimulation sensation in the neck. The battery life of the stimulator is approximately two years and cost of replacement is comparable to that of a five year supply of anti-epileptic drugs.
Vagal stimulation may offer an option of treatment before temporal lobectomy and in patients with bilateral independent epileptogenic foci.
